PE20090294A1 - Composicion farmaceutica que comprende un antagonista del factor d y su uso en el tratamiento de condiciones oculares - Google Patents

Composicion farmaceutica que comprende un antagonista del factor d y su uso en el tratamiento de condiciones oculares

Info

Publication number
PE20090294A1
PE20090294A1 PE2008000887A PE2008000887A PE20090294A1 PE 20090294 A1 PE20090294 A1 PE 20090294A1 PE 2008000887 A PE2008000887 A PE 2008000887A PE 2008000887 A PE2008000887 A PE 2008000887A PE 20090294 A1 PE20090294 A1 PE 20090294A1
Authority
PE
Peru
Prior art keywords
factor
antibody
antagonist
treatment
eye conditions
Prior art date
Application number
PE2008000887A
Other languages
English (en)
Spanish (es)
Inventor
Philip Hass
Jianping Yin
Kenneth Katschke Jr
Micah Steffek
Christian Wiesmann
Menno Van Lookeren Campagne
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39638868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090294(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20090294A1 publication Critical patent/PE20090294A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
PE2008000887A 2007-05-23 2008-05-23 Composicion farmaceutica que comprende un antagonista del factor d y su uso en el tratamiento de condiciones oculares PE20090294A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93979107P 2007-05-23 2007-05-23

Publications (1)

Publication Number Publication Date
PE20090294A1 true PE20090294A1 (es) 2009-03-27

Family

ID=39638868

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000887A PE20090294A1 (es) 2007-05-23 2008-05-23 Composicion farmaceutica que comprende un antagonista del factor d y su uso en el tratamiento de condiciones oculares

Country Status (28)

Country Link
US (6) US8007791B2 (OSRAM)
EP (1) EP2152755B1 (OSRAM)
JP (4) JP5416695B2 (OSRAM)
KR (1) KR101540126B1 (OSRAM)
CN (3) CN101754980B (OSRAM)
AR (1) AR066660A1 (OSRAM)
AU (1) AU2008256835B2 (OSRAM)
BR (1) BRPI0811142A8 (OSRAM)
CA (1) CA2683498A1 (OSRAM)
CL (1) CL2008001498A1 (OSRAM)
CY (1) CY1116062T1 (OSRAM)
DK (1) DK2152755T3 (OSRAM)
ES (1) ES2533242T3 (OSRAM)
HK (1) HK1207327A1 (OSRAM)
HR (1) HRP20150281T1 (OSRAM)
IL (2) IL201476A (OSRAM)
MX (1) MX2009012422A (OSRAM)
PE (1) PE20090294A1 (OSRAM)
PH (1) PH12013500992B1 (OSRAM)
PL (1) PL2152755T3 (OSRAM)
PT (1) PT2152755E (OSRAM)
RS (1) RS53901B1 (OSRAM)
RU (2) RU2522976C2 (OSRAM)
SG (1) SG10201401404RA (OSRAM)
SI (1) SI2152755T1 (OSRAM)
TW (2) TW201417829A (OSRAM)
WO (1) WO2008147883A1 (OSRAM)
ZA (1) ZA200907028B (OSRAM)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE412185T1 (de) * 2000-04-29 2008-11-15 Univ Iowa Res Found Diagnostika und therapeutika für makula degeneration erkrankungen
SI2500030T2 (sl) * 2005-11-04 2018-11-30 Genentech, Inc. Uporaba inhibitorjev komplementarnih procesov za zdravljenje očesnih bolezni
RS58233B1 (sr) * 2006-11-02 2019-03-29 Genentech Inc Humanizovana anti-faktor d antitela i njihove upotrebe
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
BRPI0918496A2 (pt) * 2008-09-02 2019-09-24 Novartis Ag composto inibidor bicíclico de quinase, uso do mesmo, composição farmacêutica e método para inibir a atividade da quinase pim em uma célula
AU2010208046B2 (en) 2009-01-29 2014-10-02 Forsight Vision4, Inc. Posterior segment drug delivery
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
CA2761310C (en) * 2009-05-07 2017-02-28 Charles S. Craik Antibodies and methods of use thereof
US20110165648A1 (en) 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
DK2600812T3 (da) * 2010-08-05 2021-10-18 Forsight Vision4 Inc Apparat til at behandle et øje
SI2635704T1 (sl) 2010-11-01 2017-07-31 F. Hoffmann-La Roche Ag Predvidevanje razvoja do napredne starostne makularne degeneracije s pomočjo poligenskega točkovanja
CN103402996B (zh) 2011-01-04 2015-02-11 诺瓦提斯公司 可用于治疗年龄相关性黄斑变性(amd)的吲哚化合物或其类似物
WO2012103165A2 (en) * 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
EP2867229B1 (en) 2012-06-28 2017-07-26 Novartis AG Pyrrolidine derivatives and their use as complement pathway modulators
JP6155332B2 (ja) 2012-06-28 2017-06-28 ノバルティス アーゲー ピロリジン誘導体、および補体経路調節因子としてのその使用
WO2014002051A2 (en) 2012-06-28 2014-01-03 Novartis Ag Complement pathway modulators and uses thereof
ES2712190T3 (es) 2012-06-28 2019-05-09 Novartis Ag Moduladores de la vía del complemento y sus usos
WO2014002053A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
EA201590200A1 (ru) 2012-07-12 2015-08-31 Новартис Аг Модуляторы пути активации комплемента и их применение
WO2014018625A1 (en) 2012-07-25 2014-01-30 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
US9255155B2 (en) 2013-01-31 2016-02-09 The Regents Of The University Of California Antibodies specific for urokinase-type plasminogen activator and methods of treating cancer
CA2907681C (en) 2013-03-28 2022-11-22 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US10093978B2 (en) 2013-08-12 2018-10-09 Genentech, Inc. Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms
CA2926812A1 (en) * 2013-10-07 2015-04-16 Massachusetts Eye And Ear Infirmary Methods of preventing or reducing photoreceptor cell death
CN105764533A (zh) * 2013-10-25 2016-07-13 儿童医疗中心有限公司 治疗或预防视网膜血管疾病的方法
MX2016014160A (es) 2014-05-01 2017-02-16 Genentech Inc Variantes del anticuerpo anti-factor d y sus usos.
US10239943B2 (en) 2014-05-23 2019-03-26 Celldex Therapeutics, Inc. Treatment of eosinophil or mast cell related disorders
US10435441B2 (en) * 2015-09-23 2019-10-08 Sangamo Therapeutics, Inc. HTT repressors and uses thereof
US10591481B2 (en) 2015-10-30 2020-03-17 Genentech, Inc. Methods of measuring factor D activity and potency of factor D inhibitors
CN108472382A (zh) 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 抗-因子d抗体变体缀合物及其用途
ES2870141T3 (es) 2015-10-30 2021-10-26 Hoffmann La Roche Anticuerpos anti-HtrA1 y procedimientos de uso de los mismos
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
HRP20211608T1 (hr) 2015-12-23 2022-01-21 eleva GmbH Polipeptidi za inhibiranje aktivacije komplementa
GB2553252B (en) * 2016-01-20 2019-07-31 Vitrisa Therapeutics Inc Aptamers that block the catalytic cleft of complement Factor D
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
AU2018217720A1 (en) * 2017-02-10 2019-09-05 The Trustees Of The University Of Pennsylvania Anti-factor D antibodies and uses thereof
CN109632924B (zh) * 2018-12-17 2022-02-08 上海市第一人民医院 人黄斑新生血管性疾病的血浆脂质标记物及其应用
EP3999626A4 (en) * 2019-07-18 2023-11-22 Pandorum Technologies Private Limited PROCESSES FOR CULTURE OF STEM CELLS TO OBTAIN PRODUCTS AND THEIR MODES OF PRODUCTION

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620915B2 (en) * 1993-12-23 2003-09-16 Icos Corporation Monoclonal antibodies specific for integrin α-d subunit
WO2000037638A2 (en) 1998-12-22 2000-06-29 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
US20050197285A1 (en) 1997-03-07 2005-09-08 Rosen Craig A. Human secreted proteins
US6472520B2 (en) 1997-03-21 2002-10-29 The Trustees Of Columbia University In The City Of New York Rat PEG-3 promoter
WO1999027098A2 (en) 1997-11-21 1999-06-03 Genentech, Inc. A-33 related antigens and their pharmacological uses
US6410708B1 (en) 1997-11-21 2002-06-25 Genentech, Inc. Nucleic acids encoding A-33 related antigen polypeptides
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US7282565B2 (en) 1998-03-20 2007-10-16 Genentech, Inc. PRO362 polypeptides
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
US8088386B2 (en) * 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
EP1053245A4 (en) 1998-02-09 2002-04-17 Human Genome Sciences Inc 45 HUMAN SECRETED PROTEINS
PT1054693E (pt) * 1998-02-20 2009-01-22 Genentech Inc Inibidores da activação do complemento
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
PT1490386E (pt) 1998-03-10 2008-11-24 Genentech Inc Novos polipéptidos e ácidos nucleicos que os codificam
JP2002523089A (ja) 1998-08-27 2002-07-30 インサイト・ファーマスーティカルズ・インコーポレイテッド タンパク質輸送関連分子
IL142794A0 (en) 1998-12-16 2002-03-10 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
CN1330555A (zh) * 1998-12-21 2002-01-09 路德维格癌症研究所 抗截短的vegf－d的抗体及其应用
CA2362427A1 (en) 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
RU2244748C2 (ru) 1999-03-11 2005-01-20 РМФ Диктажен С.А. Адгезивные молекулы сосудов и модуляция их функций
US6642353B1 (en) 1999-03-17 2003-11-04 Chugai Seiyaku Kabushiki Kaisha Peptide ligands for the erythropoietin receptor
AU2883900A (en) 1999-07-07 2001-01-30 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU1423601A (en) 1999-11-02 2001-05-30 Uliyanovsky Gosudarstvenny Tekhnichesky Universitet Method for cleaning liquids of ferromagnetic particles and device for the implementation thereof
EP1234030A4 (en) 1999-11-19 2003-05-07 Human Genome Sciences Inc 18 HUMAN SECRETED PROTEINS
JP2004522404A (ja) 1999-12-01 2004-07-29 ジェネンテック・インコーポレーテッド 分泌及び膜貫通ポリペプチドとそれをコードしている核酸
JP2004506413A (ja) 2000-06-23 2004-03-04 ジェネンテック・インコーポレーテッド 血管形成に関与する疾患の診断と治療のための組成物と方法
AU2001271973A1 (en) 2000-07-20 2002-02-05 Kevin P. Baker Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US20040152105A1 (en) 2002-09-06 2004-08-05 Cytos Biotechnology Ag. Immune modulatory compounds and methods
RU2232991C1 (ru) * 2003-04-09 2004-07-20 Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Способ определения функциональной активности фактора d комплемента человека
WO2006071856A2 (en) 2004-12-23 2006-07-06 Glycofi, Inc. Immunoglobulins comprising predominantly a man5glcnac2 glycoform
SI2500030T2 (sl) * 2005-11-04 2018-11-30 Genentech, Inc. Uporaba inhibitorjev komplementarnih procesov za zdravljenje očesnih bolezni
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
RS58233B1 (sr) * 2006-11-02 2019-03-29 Genentech Inc Humanizovana anti-faktor d antitela i njihove upotrebe
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
JP4349447B2 (ja) 2007-07-19 2009-10-21 トヨタ自動車株式会社 インバータ制御装置および車両

Also Published As

Publication number Publication date
RS53901B1 (sr) 2015-08-31
CN101754980A (zh) 2010-06-23
WO2008147883A8 (en) 2013-05-23
JP2017197577A (ja) 2017-11-02
SI2152755T1 (sl) 2015-05-29
KR101540126B1 (ko) 2015-07-28
ES2533242T3 (es) 2015-04-08
TW201417829A (zh) 2014-05-16
WO2008147883A1 (en) 2008-12-04
CL2008001498A1 (es) 2009-06-12
MX2009012422A (es) 2009-12-04
US8497094B2 (en) 2013-07-30
EP2152755A1 (en) 2010-02-17
US8007791B2 (en) 2011-08-30
JP2014087346A (ja) 2014-05-15
US8268310B2 (en) 2012-09-18
KR20100033973A (ko) 2010-03-31
US20110282034A1 (en) 2011-11-17
AU2008256835A1 (en) 2008-12-04
TW200904471A (en) 2009-02-01
HK1207327A1 (en) 2016-01-29
PL2152755T3 (pl) 2015-06-30
CN104367999A (zh) 2015-02-25
RU2014113046A (ru) 2015-10-10
DK2152755T3 (en) 2015-03-02
RU2522976C2 (ru) 2014-07-20
EP2152755B1 (en) 2014-12-31
IL248552A0 (en) 2016-12-29
US20130052685A1 (en) 2013-02-28
IL201476A (en) 2016-11-30
CY1116062T1 (el) 2017-02-08
CN101754980B (zh) 2014-10-29
PT2152755E (pt) 2015-04-01
SG10201401404RA (en) 2014-08-28
US20090181017A1 (en) 2009-07-16
CN107096029B (zh) 2021-02-26
JP5416695B2 (ja) 2014-02-12
ZA200907028B (en) 2010-12-29
JP2010528047A (ja) 2010-08-19
HK1139161A1 (en) 2010-09-10
PH12013500992A1 (en) 2016-01-25
US20160272726A1 (en) 2016-09-22
JP2016145205A (ja) 2016-08-12
RU2009147744A (ru) 2011-06-27
TWI419704B (zh) 2013-12-21
IL201476A0 (en) 2010-05-31
PH12013500992B1 (en) 2018-12-14
BRPI0811142A8 (pt) 2018-12-18
CA2683498A1 (en) 2008-12-04
US20130302333A1 (en) 2013-11-14
US20180079826A1 (en) 2018-03-22
HRP20150281T1 (hr) 2015-04-10
CN107096029A (zh) 2017-08-29
AU2008256835B2 (en) 2013-08-01
BRPI0811142A2 (pt) 2014-12-23
AR066660A1 (es) 2009-09-02

Similar Documents

Publication Publication Date Title
PE20090294A1 (es) Composicion farmaceutica que comprende un antagonista del factor d y su uso en el tratamiento de condiciones oculares
AR082163A1 (es) Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos
NZ706377A (en) Il-6 antagonists and uses thereof
PE20060376A1 (es) ANTICUERPO MONOCLONAL HUMANIZADO O QUIMERICO COMO INHIBIDOR DE hIL-3
PE20081186A1 (es) Metodos y composiciones para el tratamiento de enfermedades alergicas
PE20211767A1 (es) Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y metodos de uso de anticuerpos anti-hla-g
HRP20211641T1 (hr) Bispecifična protutijela anti-vegf/anti-ang-2 i njihova primjena u liječenju vaskularnih očnih bolesti
PE20110668A1 (es) Anticuerpos anti-linfopoyetina estromal timica (anti-tslp)
MY208416A (en) Antibody capable of binding to thymic stromal lymphopoietin and use thereof
NO20074867L (no) Antistoffer mot CCR5 og anvendelser derav
ECSP099656A (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
PE20200734A1 (es) Anticuerpos anti-tgf-beta y su uso
PE20091196A1 (es) Anticuerpos contra el vegf completamente humano, composiciones y metodos
AR070346A1 (es) Anticuerpo especifico del receptor de linfopoyetina estromal timica (tslpr) y usos en trastornos inflamatorios e inflamatorios alergicos
AR058955A1 (es) Inmunglobulinas que se unen a interleuquina 13
AR096895A2 (es) Anticuerpo que se une a la citoquina, linfopoyetina estromal tímica (tslp)
PE20120899A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
AR075925A1 (es) Anticuerpos anti-alfa5beta1 (alfa5beta1: glicoproteina integrina) y sus usos
EA201490053A1 (ru) Антитела, которые связываются с ox40, и их применение
PE20241623A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos
PE20142322A1 (es) Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc
MY186351A (en) Multispecific antibodies
DE602005021694D1 (de) Kombinationstherapien gegen multiple toll-like-rezeptoren und ihre verwendung
CL2012000229A1 (es) Anticuerpo humano aislado o un fragmento del mismo de unión al antígeno, que se une específicamente a la angiopoyetina-2 humana (hang-2) pero que no se une sustancialmente a la hang-1; composición farmacéutica que lo comprende; y su uso para el tratamiento de un tumor, hipertensión, diabetes, edema, enfermedad renal u ocular.

Legal Events

Date Code Title Description
FC Refusal
FG Grant, registration
FD Application declared void or lapsed